Explore the exciting world of Neurocrine Biosciences (NBIX -0.68%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Feb. 19, 2025. The video was published on March 26, 2025.
S&P 500
6,024.84
+0.3%
+$18.96
DJI
42,803.00
+0.1%
+$41.24
NASDAQ
19,654.39
+0.3%
+$63.15
Bitcoin
109,114.00
+1.2%
+1,262.23
AAPL
$202.71
+0.6%
+$1.26
AMZN
$215.87
-0.5%
-$1.11
GOOG
$181.65
+2.3%
+$4.02
META
$697.84
+0.5%
+$3.78
MSFT
$469.29
-0.7%
-$3.46
NVDA
$142.98
+0.2%
+$0.34
TSLA
$318.19
+3.1%
+$9.61
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
By Motley Fool YouTube
–
Mar 26, 2025 at 7:00PM
NASDAQ: NBIX
Neurocrine Biosciences
Market Cap
$12B
Today's Change
(-0.68%) -$0.86
Current Price
$124.87
Price as of June 10, 2025, 12:16 p.m. ET
Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.
Stocks Mentioned
Neurocrine Biosciences
NBIX
$124.87
(-0.68%)
$0.86
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Neurocrine Biosciences Stock Sank Today
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Tops Expectations in Q3
Why Neurocrine Biosciences Stock Was Tumbling This Week
Neurocrine Biosciences' Revenue and Adjusted Income Surge
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.